Adverse event reporting with selective serotonin-reuptake inhibitors

Annals of Pharmacotherapy

Volumn 37, Issue 10, 2003, Pages 1387-1391

  Hartnell, Nicole R ^a   Wilson, James P ^b,e   Patel, Nick C ^b,c   Crismon, M Lynn ^b,d  

^a DALHOUSIE UNIVERSITY   (Canada)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^c Austin State Hospital   (United States)

^d Austin Fire Department   (United States)

^e The Center for Molecular Carcinogenesis and Toxicology   (United States)

Author keywords

Adverse events; Antidepressants; SSRIs; Weber effect

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ARTICLE; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG MARKETING; DRUG SURVEILLANCE PROGRAM; HUMAN; PRIORITY JOURNAL; UNITED STATES; VALIDATION PROCESS;

ADVERSE DRUG REACTION REPORTING SYSTEMS; DATA COLLECTION; HUMANS; LONGITUDINAL STUDIES; MENTAL DISORDERS; PHARMACOEPIDEMIOLOGY; PRODUCT SURVEILLANCE, POSTMARKETING; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS;

EID: 0141557914     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1C522     Document Type: Article

References (23)

1. Weber JCP. Epidemiology of adverse reactions to nonsteroidal antiinflammatory drugs. In: Rainsford KD, Velo GP, eds. Advances in inflammation research. Vol. 6. New York: Raven Press, 1984:1-7.
2. Fung M, Kwong K, Mockbee C, Hornbuckel K, Numiz E. Analysis of the occurrence of Weber Effect in spontaneous adverse event reporting (abstract). Pharmacoepidemiol Drug Saf 1999;8:S073.
3. Brodovicz K, Hostelley L, Sharrar R. The Weber Effect - is it real (abstract)? Pharmacoepidemiol Drug Saf 2001;10:S128.
4. Fife D, Wallenstein E. Temporal patterns of NSAID spontaneous adverse event reports: the Weber Effect revisited. Drug Saf 2001;24:233-7.
5. Weber JCP. Mathematical models in adverse drug reaction assessment. In: D'Arcy FF, Griffin JP, eds. Iatrogenic diseases. Oxford: Oxford University Press, 1986:102-7.
6. Schatzberg AF. New indications for antidepressants. J Clin Psychiatry 2000;61(suppl 11):9-17.
7. Package insert. Prozac (fluoxetine). Indianapolis: Eli Lilly and Co., December 2002.
8. Package insert. Zoloft (sertraline). New York: Pfizer, December 2002.
9. Package insert. Paxil (paroxetine). Research Triangle Park, NC: Glaxo-SmithKline, December 2002.
10. Package insert. Luvox (fluvoxamine). West Baudette, MN: Solvay Pharmaceuticals, December 2002.
11. Package insert. Celexa (citalopram). St. Louis: Forest Pharmaceuticals, December 2002.
12. Package insert. Lexapro (escitalopram). St. Louis: Forest Pharmaceuticals, December 2002.
13. Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 2000;58:19-36.
14. Goldstein BJ, Goodnick PJ. Selective serotonin reuptake inhibitors in the treatment of affective disorders - III. Tolerability, safety and pharmacoeconomics. J Psychopharmacol 1998;12(suppl B):S55-87.
15. FDA Spontaneous Reporting System (SRS): adverse reactions reported to FDA from 1969 thru August 1998 (on CD-ROM). www.ntis.gov/fcpc/cpn8534.htm (accessed 2002 Mar 21).
16. FDA quarterly data extract from the Adverse Event Reporting System (AERS) (Raw data file on CD-Rom). www.ntis.gov/fcpc/cpn8762.htm (accessed 2002 Mar 21).
17. Corre K. Adverse drug reaction processing in the United States and its dependence on physician reporting: zomepirac (Zomax) as a case in point. Ann Emerg Med 1988;17:65-9.
18. Burke LB, Kennedy DL, Hunter JR. Spontaneous reporting in the United States. In: Hartzema AG, Porta M, Tilson HH, eds. Pharmacoepidemiology: an introduction. 3rd ed. Cincinnati: Harvey Whitney Books, 1998: 213-35.
19. Cobert B, Silvey J. The internet and drug safety: what are the implications for pharmacovigilance? Drug Saf 1999;20:95-107.
20. FDA orange book. www.fda.gov/cder/ob/default.htm (accessed 2002 Mar 5).
21. Teicher MH, Glod C, Cole JO. Emergence of intense suicidal preoccupation during fluoxefine treatment. Am J Psychiatry 1990;147:207-10.
22. Office of Drug Safety Annual Report. FDA Center for Drug Evaluation and Research. www.fda.gov/cder/Offices/drugsafety/AnnRep2001/annualreport2001.htm (accessed 2002 Mar 5).
23. Goldman SA. Limitations and strengths of spontaneous reports data. Clin Ther 1998;20(suppl C):C40-4.